spacer
home > pmps > winter 2002 > nasal delivery of vaccines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nasal Delivery of Vaccines

The nasal delivery of vaccines has recently emerged as an attractive alternative to injection. Nasal vaccination has the advantage that it elicits both local and systemic immune responses. The mucosal immune response is rapid and nasal vaccines may also induce protection in distant mucosal sites. Correct formulation and adequate distribution to the nasal mucosa are, however, essential for efficacy and safety. The complexity of nasal geometry represents a major challenge for efficient intranasal vaccination, and current delivery devices may prove inadequate in meeting future safety and reliability requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Per Gisle Djupesland, Founder, Head of R&D and Chairman of OptiNose AS
Dr Per Gisle Djupesland is Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing devices based on a novel technology for the nasal delivery of drugs and vaccines. Dr Djupesland is a specialist in Otorhinolaryngology.

He has a PhD in Nasal Physiology and Aerodynamics from the University of Oslo and has also been Research Fellow at the University of Toronto, Canada. Dr Djupesland holds a degree in International Health and Tropical Medicine from the University of Pierre and Marie Curie in Paris, France, and has been Project Manager for a large-scale vaccination trial for the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement